Background: Antibiotics used to treat Clostridioides difficile infection (CDI) can predispose patients to recurrent CDI (rCDI). Gut microbiome restoration by fecal microbiota transplantation is recommended by multiple guidelines after ≥2 episodes of rCDI, with no guideline-recommended options to restore the microbiome earlier in the course of CDI. RBX2660 is a standardized, microbiota-based live biotherapeutic being [...]

Background: Clostridioides difficile is an opportunistic pathogen that causes an estimated 500,000 infections per year in the United States. RBX2660, a standardized, microbiota-based live biotherapeutic, is being investigated as a treatment option for recurrent C. difficile infection (rCDI). RBX2660 has demonstrated consistent tolerability and efficacy in reducing rCDI across 6 clinical studies. We present a [...]